Drug Profile
Research programme: antibody drug conjugate therapeutics - NBE Therapeutics
Alternative Names: CD19 targeting antibody drug conjugates- NBE Therapeutics; CD30 targeting antibody drug conjugates- NBE Therapeutics; HER2 targeting antibody drug conjugates- NBE Therapeutics; NBE 001- NBE Therapeutics; PNU-159682-brentuximab antibody drug conjugate - NBE Therapeutics; PNU-159682-cAC10 antibody drug conjugate - NBE Therapeutics; PNU-159682-trastuzumab antibody drug conjugate - NBE TherapeuticsLatest Information Update: 28 Jul 2023
Price :
$50
*
At a glance
- Originator NBE-Therapeutics
- Developer NBE-Therapeutics; SOTIO
- Class Anthracyclines; Antineoplastics; Cytostatic antibiotics; Drug conjugates; Immunoconjugates; Immunotherapies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Solid tumours
Most Recent Events
- 28 Jul 2023 No recent reports of development identified for preclinical development in Solid-tumours in Swaziland (Parenteral)
- 08 Oct 2019 NBE Therapeutics announces intention to submit IND application in first half of 2020
- 29 Jan 2019 NBE Therapeutics has patent protection for anthracycline-based antibody drug conjugates platform and SMAC-technology in USA